VIGIL NEUROSCIENCE INC (VIGL) Stock Price, Forecast & Analysis
USA - NASDAQ:VIGL - US92673K1088 - Common Stock
VIGL Key Statistics, Chart & Performance
The current stock price of VIGL is 8.05 USD. In the past month the price increased by 0.75%. In the past year, price increased by 170.13%.
VIGL Latest News, Press Relases and Analysis
VIGL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.88 | 381.89B | ||
| AMGN | AMGEN INC | 13.55 | 159.15B | ||
| GILD | GILEAD SCIENCES INC | 15.05 | 152.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.25 | 107.94B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.94 | 66.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 830.12 | 55.49B | ||
| ARGX | ARGENX SE - ADR | 61.89 | 51.10B | ||
| INSM | INSMED INC | N/A | 38.66B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5 | 34.04B | ||
| NTRA | NATERA INC | N/A | 26.99B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.14B | ||
| BIIB | BIOGEN INC | 8.99 | 22.05B |
Related stock screener links
About VIGL
Company Profile
Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. The company is headquartered in Watertown, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2022-01-07. The firm is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. The company is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The firm is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.
Company Info
VIGIL NEUROSCIENCE INC
100 Forge Road, Suite 700
Watertown MASSACHUSETTS US
Employees: 69
Phone: 18572544445
VIGIL NEUROSCIENCE INC / VIGL FAQ
What does VIGIL NEUROSCIENCE INC do?
Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. The company is headquartered in Watertown, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2022-01-07. The firm is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. The company is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The firm is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.
What is the stock price of VIGIL NEUROSCIENCE INC today?
The current stock price of VIGL is 8.05 USD.
What is the dividend status of VIGIL NEUROSCIENCE INC?
VIGL does not pay a dividend.
How is the ChartMill rating for VIGIL NEUROSCIENCE INC?
VIGL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is VIGIL NEUROSCIENCE INC (VIGL) stock traded?
VIGL stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of VIGIL NEUROSCIENCE INC (VIGL)?
VIGIL NEUROSCIENCE INC (VIGL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.09).
What is the market capitalization of VIGL stock?
VIGIL NEUROSCIENCE INC (VIGL) has a market capitalization of 375.69M USD. This makes VIGL a Small Cap stock.
VIGL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to VIGL. When comparing the yearly performance of all stocks, VIGL is one of the better performing stocks in the market, outperforming 98.76% of all stocks.
VIGL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VIGL. VIGL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
VIGL Financial Highlights
Over the last trailing twelve months VIGL reported a non-GAAP Earnings per Share(EPS) of -2.09. The EPS increased by 1.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -80.94% | ||
| ROE | -133.18% | ||
| Debt/Equity | 0 |
VIGL Forecast & Estimates
13 analysts have analysed VIGL and the average price target is 8.16 USD. This implies a price increase of 1.37% is expected in the next year compared to the current price of 8.05.